Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients
Article first published online: 2 MAR 2005
British Journal of Clinical Pharmacology
Volume 59, Issue 5, pages 520–523, May 2005
How to Cite
Davies, J., Gavin, A., Band, M., Morris, A. and Struthers, A. (2005), Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. British Journal of Clinical Pharmacology, 59: 520–523. doi: 10.1111/j.1365-2125.2005.02363.x
- Issue published online: 2 MAR 2005
- Article first published online: 2 MAR 2005
- Received 1 October 2004 Accepted 23 November 2004
To assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics.
Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months’ treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase.
Compared with placebo, spironolactone reduced systolic BP by 15.6 ± 46.1 mmHg (P = 0.005, 95% CI 2.7–28.5 mmHg), PIIINP by 0.6 ± 0.3 µg l−1 (P = 0.04, 95% CI 0.02–1.1 µg l−1) and PWV by 0.6 ± 0.2 m s−1 (P = 0.008, 95% CI 0.18–1.02 m s−1).
Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.